(Total Views: 605)
Posted On: 10/24/2025 5:47:22 PM
Post# of 158792
The author did not mention his source or LL but in the footnotes of the article there is mention of the Yang and Seethamraju LL studies.
References
World Health Organization. No Time to Wait: Securing the Future from Drug Resistant Infections. WHO; 2019.
Seethamraju H, Smith DM, et al. CCR5 blockade in patients with severe COVID 19 treated with leronlimab : a case series. J Transl Autoimmun. 2021;4:100103.
Yang OO, Pasikhova Y, et al. CCR5 blockade with leronlimab restores immune homeostasis in critical COVID 19. Clin Infect Dis. 2022;74(7):1180–1183.
Geoffrey Fourqurean is the author.
Geoffrey Fourqurean is a neuroscientist and patient advocate with experience in immunology, infectious disease, and host-directed therapies. He writes about global health, HIV cure strategies, and antimicrobial resistance.
https://www.europeanhhm.com/articles/antimicr...ed-therapy
Science is reading our studies.
References
World Health Organization. No Time to Wait: Securing the Future from Drug Resistant Infections. WHO; 2019.
Seethamraju H, Smith DM, et al. CCR5 blockade in patients with severe COVID 19 treated with leronlimab : a case series. J Transl Autoimmun. 2021;4:100103.
Yang OO, Pasikhova Y, et al. CCR5 blockade with leronlimab restores immune homeostasis in critical COVID 19. Clin Infect Dis. 2022;74(7):1180–1183.
Geoffrey Fourqurean is the author.
Geoffrey Fourqurean is a neuroscientist and patient advocate with experience in immunology, infectious disease, and host-directed therapies. He writes about global health, HIV cure strategies, and antimicrobial resistance.
https://www.europeanhhm.com/articles/antimicr...ed-therapy
Science is reading our studies.
(16)
(0)
